Erik T. Bodor

871 total citations
16 papers, 688 citations indexed

About

Erik T. Bodor is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Erik T. Bodor has authored 16 papers receiving a total of 688 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Pharmacology. Recurrent topics in Erik T. Bodor's work include Drug Transport and Resistance Mechanisms (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers) and Diabetes Treatment and Management (3 papers). Erik T. Bodor is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers) and Diabetes Treatment and Management (3 papers). Erik T. Bodor collaborates with scholars based in United States, Japan and Germany. Erik T. Bodor's co-authors include Stefan Offermanns, Andreas Gille, Kashan Ahmed, T. Kendall Harden, Gary L. Waldo, Shelley B. Hooks, James Corbitt, Nicholas Bodor, Andrejs M. Krumins and Teruo Murakami and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and British Journal of Pharmacology.

In The Last Decade

Erik T. Bodor

14 papers receiving 673 citations

Peers

Erik T. Bodor

CMN

SURGE

PHYSI

EDM

Alíz Szabó Hungary

A.V. Wallace United Kingdom

Duncan Armstrong United Kingdom

J.M. Dypbukt Sweden

Pingzheng Zhou China

Rajeshwary Ghosh United States

Yuliya Dobrydneva United States

Seung-Ju Yang South Korea

Rita Roberti Italy

Zhenjie Zhuang China

Alíz Szabó Hungary

Erik T. Bodor

511 ×1.5

190 ×1.9

CMN

95 ×1.1

SURGE

82 ×1.1

PHYSI

48 ×0.6

EDM

Citations per year, relative to Erik T. Bodor Erik T. Bodor (= 1×) peers Alíz Szabó

Countries citing papers authored by Erik T. Bodor

Since Specialization

Citations

This map shows the geographic impact of Erik T. Bodor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik T. Bodor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik T. Bodor more than expected).

Fields of papers citing papers by Erik T. Bodor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik T. Bodor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik T. Bodor. The network helps show where Erik T. Bodor may publish in the future.

Co-authorship network of co-authors of Erik T. Bodor

This figure shows the co-authorship network connecting the top 25 collaborators of Erik T. Bodor. A scholar is included among the top collaborators of Erik T. Bodor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik T. Bodor. Erik T. Bodor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

White, Alex D., et al.. (2026). GLP ‐ 1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models. Diabetes Obesity and Metabolism. 28(3). 2317–2328.

Murakami, Teruo, Erik T. Bodor, & Nicholas Bodor. (2023). Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations. Expert Opinion on Drug Metabolism & Toxicology. 19(3). 139–148. 9 indexed citations

Murakami, Teruo, Erik T. Bodor, & Nicholas Bodor. (2023). Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties. Expert Opinion on Drug Metabolism & Toxicology. 19(3). 129–137. 18 indexed citations

Murakami, Teruo, Erik T. Bodor, & Nicholas Bodor. (2021). Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs. Expert Opinion on Drug Metabolism & Toxicology. 17(5). 555–580. 13 indexed citations

Murakami, Teruo, Erik T. Bodor, & Nicholas Bodor. (2019). Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opinion on Drug Metabolism & Toxicology. 16(1). 59–78. 23 indexed citations

Bodor, Nicholas, et al.. (2017). Potent analogues of etiprednol dicloacetate, a second generation of soft corticosteroids. Journal of Pharmacy and Pharmacology. 69(12). 1745–1753. 2 indexed citations

Bodor, Erik T., et al.. (2016). Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin. Journal of Pharmaceutical Sciences. 105(9). 2873–2878. 2 indexed citations

Johnston, Christopher A., Francis S. Willard, Zoey L. Fredericks, et al.. (2010). Structures of G [alpha [superscript i1]] Bound to a GDP-Selective Peptide Provides Insight into Guanine Nucleotide Exchange. Structure. 13.

Bodor, Erik T. & Stefan Offermanns. (2007). Nicotinic acid: an old drug with a promising future. British Journal of Pharmacology. 153(S1). S68–75. 104 indexed citations

10.

Gille, Andreas, Erik T. Bodor, Kashan Ahmed, & Stefan Offermanns. (2007). Nicotinic Acid: Pharmacological Effects and Mechanisms of Action. The Annual Review of Pharmacology and Toxicology. 48(1). 79–106. 245 indexed citations

11.

Johnston, Christopher A., Francis S. Willard, Zoey L. Fredericks, et al.. (2005). Structure of Gαi1 Bound to a GDP-Selective Peptide Provides Insight into Guanine Nucleotide Exchange. Structure. 13(7). 1069–1080. 65 indexed citations

12.

Bodor, Erik T., et al.. (2004). C(8)-Substituted 1-azabicyclo[3.3.1]non-3-enes: a novel scaffold for muscarinic receptor ligands. Bioorganic & Medicinal Chemistry. 12(9). 2357–2367. 1 indexed citations

13.

Bodor, Erik T., et al.. (2004). Delineation of ligand binding and receptor signaling activities of purified P2Y receptors reconstituted with heterotrimeric G proteins. Purinergic Signalling. 1(1). 43–49. 3 indexed citations

14.

Hooks, Shelley B., Gary L. Waldo, James Corbitt, et al.. (2003). RGS6, RGS7, RGS9, and RGS11 Stimulate GTPase Activity of Gi Family G-proteins with Differential Selectivity and Maximal Activity. Journal of Biological Chemistry. 278(12). 10087–10093. 130 indexed citations

15.

Bodor, Erik T., Gary L. Waldo, Shelley B. Hooks, et al.. (2003). Purification and Functional Reconstitution of the Human P2Y12 Receptor. Molecular Pharmacology. 64(5). 1210–1216. 64 indexed citations

16.

Bodor, Erik T., et al.. (2003). C(8) Substituted 1-Azabicyclo[3.3.1]non-3-enes and C(8) Substituted 1-Azabicyclo[3.3.1]nonan-4-ones: Novel Muscarinic Receptor Antagonists. Journal of Medicinal Chemistry. 46(11). 2216–2226. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact